Spatial and temporal control of transgene expression <i>in vivo</i> using a heat‐sensitive promoter and MRI‐guided focused ultrasound

Guilhon, E.; Voisin, Pierre; Zwart, Jacco A. de; Quesson, Bruno; Salomir, Rarès; Maurange, Cédric; Bouchaud, Véronique; Смирнов, П. Р.; Verneuil, Hubert de; Vekris, Antoine; Canioni, Paul; Moonen, Chrit

doi:10.1002/jgm.345

Cited by 77 publications

(55 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar promoter characteristics were reported in vivo in a number of organs, such as skin (12), muscle (13), prostate (14), and liver (15), that were genetically modified using either a virus or a plasmid to express a reporter gene under the control of the HSP promoter. Noninvasive in vivo local heating, and thus local activation of gene expression, could be achieved with high-intensity focused ultrasound (HIFU) (15)(16)(17), but a subtle compromise has to be found in the heating strategy, because excessive tissue heating can induce tissue damage and necrosis. Local temperature distribution can be monitored with magnetic resonance temperature imaging (MRI) to evaluate the efficacy of heat-induced gene activation technique as well as safety.…”

mentioning

confidence: 99%

Image-guided, noninvasive, spatiotemporal control of gene expression

Deckers

Quesson

Arsaut

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

mentioning

confidence: 99%

Image-guided, noninvasive, spatiotemporal control of gene expression

Deckers

Quesson

Arsaut

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

“…Previous studies have demonstrated that 39-43 C should be regarded as an effective hyperthermia range to generate desired treatment effects. [5][6][7][8][9][10][11] The temperature higher than 44 C is reported as a cytotoxic temperature which can make cells undergo coagulative necrosis, while essentially no significant cell death would occur below 41 C even with 1-h exposures. 6,[16][17][18][19] It is understandable that, due to different cell and vessel types as well as particular experimental situations, the lower temperature limit for in vitro cell toxicity and in vivo vascular damage reported in previous literatures might vary between 42 and 44 C. Here, a temperature limit of 44 C is targeted to investigate the approximate DC range for the safe hyperthermia therapy.…”

Section: -mentioning

confidence: 99%

“…These exposures can achieve relatively stable temperature elevation within a hyperthermia range of 39-44 C. 6,7 Numerous research studies and clinical reports support the finding that ultrasound-induced hyperthermia can provide a promising and potentially much safer alternative to conventional ultrasound-based cancer therapy. [6][7][8][9][10][11] Despite growing interest in utilizing pHIFU-induced hyperthermia for cancer treatment, it is also suggested that the elevated temperature at the focus should be restricted to be lower than 44 C to avoid undesirable bioeffects. 5,6 However, most researchers just simply empirically select HIFU parameters for different applications.…”

mentioning

confidence: 99%

Controllable in vivo hyperthermia effect induced by pulsed high intensity focused ultrasound with low duty cycles

Hwang

Chen

et al. 2012

Appl. Phys. Lett.

View full text Add to dashboard Cite

“…As it can be applied to thermal ablation, MRI may be useful for guiding and monitoring these procedures. Indeed, promising results have emerged on the MRI monitoring of FUS with heat-activated liposomal agents and heatactivated gene therapy (90,91).…”

Section: Future Development Of Technologymentioning

confidence: 99%

Current status and future potential of MRI‐guided focused ultrasound surgery

Jólesz

McDannold

2008

Magnetic Resonance Imaging

112

View full text Add to dashboard Cite

The combination of the imaging abilities of magnetic resonance imaging (MRI) with the ability to delivery energy to targets deep in the body noninvasively with focused ultrasound presents a disruptive technology with the potential to significantly affect healthcare. MRI offers precise targeting, visualization, and quantification of temperature changes and the ability to immediately evaluate the treatment. By exploiting different mechanisms, focused ultrasound offers a range of therapies, ranging from thermal ablation to targeted drug delivery. This article reviews recent preclinical and tests clinical of this technology. WHILE ITS POTENTIAL has been recognized for decades (1-4), focused ultrasound (FUS) therapy has been in the incubation phase for a long time. Although it has been tested in numerous animal experiments, its widespread clinical realization has lagged, primarily due to the lack of intraprocedural accurate temperature monitoring. When the idea of MRI-guidance was introduced in connection with FUS and MRI thermometry during sonication was demonstrated (5,6), it was anticipated that MR-guided FUS surgery (MRgFUS) would be widely accepted clinically within a few years. Despite these early expectations, there has been relatively slow progress in the clinical implementation of MRgFUS.Early development concentrated primarily on breast tumors (benign fibroadenoma (7,8) and malignant breast cancer (9,10)). These early implementations of the MRgFUS technology motivated the improvement of transducer technology from single-element transducers to MRI-compatible multielement phase arrays (11). There was also significant progress in MRI thermometry and its use to monitor and control sonications. Importantly, too, methods were developed to robustly quantify temperature changes (12). At first, only 2D temperature maps were obtained by MRI to allow for accurate targeting of the beam (13). Later these thermal images were used to generate maps of the thermal dose (14) that could then be used to tailor the energy deposition using closed-loop feedback control (15). This preclinical work led to the development of the first commercial system by InSightec (Haifa, Israel), the Exablate 2000, the first implementation of a fully integrated MRgFUS system that combined a phased array transducer, a computer-controlled robotic positioner, and a workstation that integrated control based on MR thermometry.The early limited clinical trials of breast tumor treatment (8 -10,16,17) were followed by the first major clinical application: the noninvasive therapy of benign uterine fibroids (18,19). The successful Phase I trial was followed by a multicenter . These clinical trials led to the approval of this technology for the treatment of uterine fibroids in several countries, including the United States. Examples of MR thermometry and postablation imaging of a uterine fibroid ablation are shown in Figure 1.The success of uterine fibroid ablation has invigorated the entire field. Technology has rapidly improved and clinical applications ke...

show abstract

Spatial and temporal control of transgene expression in vivo using a heat‐sensitive promoter and MRI‐guided focused ultrasound

Abstract: Heating with MRI-FUS allows a tight and non-invasive control of transgene expression in a tumour.

Cited by 77 publications

References 41 publications

Image-guided, noninvasive, spatiotemporal control of gene expression

Image-guided, noninvasive, spatiotemporal control of gene expression

Controllable in vivo hyperthermia effect induced by pulsed high intensity focused ultrasound with low duty cycles

Current status and future potential of MRI‐guided focused ultrasound surgery

Contact Info

Product

Resources

About